KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell CarcinomaBusiness Wire • 04/27/25
Merck absorbs $200 million in tariff costs into its earnings and full-year outlookMarket Watch • 04/24/25
Gardasil Sales Decline — Again. Can Dow Jones Stock Merck Take The Hit?Investors Business Daily • 04/24/25
Merck Stock Slumps Ahead Of Q1 Earnings: Can Bulls Find Relief In Buying Pressure?Benzinga • 04/23/25
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?Zacks Investment Research • 04/22/25
Merck: Now A Single-Digit P/E With Double-Digit EPS Growth, Technical SupportSeeking Alpha • 04/22/25
Ahead of Merck (MRK) Q1 Earnings: Get Ready With Wall Street Estimates for Key MetricsZacks Investment Research • 04/18/25
One Sector Paying Big Dividends Is Off to the Best Start in 25 Years Despite Tariffs24/7 Wall Street • 04/18/25
Microfiltration Membranes Market Research - Global Forecast to 2029 with Merck, Sartorius, and Pall LeadingGlobeNewsWire • 04/17/25